. 2008 Apr 25;9(1):36. doi: 10.1186/1465-9921-9-36

Table 4.

Immune recognition to sodA peptides among study participants

Subject	Age^a/Sex^b/Race^c	Site of Involvement^d	sodA*	Subject	Age^a/Race^b/Sex^c	Site of Involvement^d	sodA*
Sarcoidosis 6	50, F, AA	P, C	70	Control 1	43, F, AA	None	0
Sarcoidosis 7	31, M, AA	CNS, P, C	150	Control 2	38, F, C	None	0
Sarcoidosis 8	34, F, C	P	100	Control 3	27, F, AA	None	10
Sarcoidosis 9	55, F, AA	P	65	Control 4	33, F, AA	None	0
Sarcoidosis 10	56, M, C	P	0	Control 5	23, M, C	None	0
Sarcoidosis 11	47, F, C	P, CNS	0	Control 6	25, F, C	None	0
Sarcoidosis 12	42, M, C	P	0	Control 7	31, M, AA	None	0
Sarcoidosis 13	51, M, AA	P	110	Control 8	52, F, C	None	0
Sarcoidosis 14	45, M, C	P, C	0	Control 9	32, F, C	None	0
Sarcoidosis 15	34, F, C	P	0	Control 10	34, F, AA	None	0
Sarcoidosis 16	30, M, C	P	160	Control 11	29, M, C	None	0
Sarcoidosis 17	33, M, C	P	0	Control 12	52, F, C	None	0
				Control 13	35, F, C	None	0
				Control 14	57, F, C	None	0
				Control 15	54, F, C	None	0
PPD+ 1	49, F, C	Latent	360	Control 16	57, F, C	None	10
PPD+ 2	50, F, AA	Latent	50	Control 17	55, F, AA	None	0
PPD+ 3	42, F, AA	Latent	100	Control 18	37, M, AA	None	0
PPD+ 4	58, M, AA	Latent	65	Control 19	44, F, C	None	0
PPD+ 5	50, F, C	Latent	50	Control 20	32, F, AA	None	0
PPD+ 6	60, F, AA	Latent	0	Control 21	32, F, AA	None	500
PPD+ 7	38, F, C	Latent	0	Control 22	27, F, AA	None	0
PPD+ 8	49, F, C	Latent	0	Control 23	42, F, AA	None	0
PPD+ 9	42, M, AA	Latent	55	Control 24	32, M, AA	None	0
PPD+ 10	51, F, C	Latent	0	Control 25	26, F, AA	None	0
PPD+ 11	30, M, C	Latent	0	Control 26	50, M, AA	None	0

^aAge in years; ^bAA, African-American; C, Caucasian; ^cF, female, M, male; ^dP, Pulmonary; C, Cutaneous; CNS, Central Nervous System; ABD, Abdominal; *Inteferon-γ producing spot-forming cells per million PBMC